While targeting the PD1/PDL1 axis with therapeutic antibodies (eg. nivolumab / atezolizumab) offers unprecedented clinical benefit in metastatic melanoma and lung cancer, durable responses are observed only in a fraction of patients. Current lines of investigations on such therapies mainly aim at evaluating and identifying novel drugs capable of leveraging the efficacy of PD-1/PD-L1 axis blockade. In this respect, Explicyte offers a range of syngeneic mice models of anti-PD-1 and/or anti-PD-L1 antibody therapy. Furthermore, preclinical efficacy data can be strengthened by ancillary immune cell profiling and MOA studies – relying on key immunological markers quantification, within the tumor or in peripheral organs - thereby allowing a deep interrogation of the immune response elicited by test compounds. Our models can also support for the identification of innovative and novel predictive biomarkers.
Download our "in vivo monitoring and flow cytometry-based immunoprofiling on syngeneic tumor models " white paper
Robust preclinical models of anti-PD-1 /anti-PD-L1 antibody therapy
- Robust treatment protocols using classical well-described antibody clones, in line with published literature data
- Syngeneic tumor models - to evaluate drug effects on the anti-tumor immune response in the presence of a functionally immunocompetent system.
- Anti-PD-L1 responding & non-responding tumor models, including colon, melanoma, and unique bioluminescent glioblastoma cancer models.